Semaglutide

Semaglutide, sold under the brand names Ozempic, Wegovy and Rybelsus, is an antidiabetic medication used for the treatment of type 2 diabetes and an anti-obesity medication used for long-term weight management, developed by Novo Nordisk in 2012.Semaglutide is a GLP-1 receptor agonist, meaning that it mimics the action of the human incretin glucagon-like peptide-1 (GLP-1), thereby increasing insulin secretion and increasing blood sugar disposal and improving glycemic control.

Read more in the app

Semaglutide leads to greater weight loss in women than men with HF and improves HF symptoms

Revolutionary Weight Loss: Largest Ever Obesity Study Showcases Semaglutide’s Promise

Beyond Weight Loss: Semaglutide Delivers Major Heart Health Benefits

Vanishing Fat: Semaglutide’s Triumph Over HIV Liver Disease

After treatment with semaglutide, newly diagnosed Type 1 diabetes patients needed little or no insulin

Higher doses of oral semaglutide improves blood sugar control and weight loss

Cutting Alcohol Consumption in Half – Scientists Discover Surprising Side Effect of Obesity Drug Semaglutide

Weight Loss Success: Semaglutide Turns the Scales on Teen Obesity

Weight Loss Medications Could Be Sold for Lower Prices: Semaglutide, Bupropion, Naltrexone, Tirzepatide

New Study: Taking Semaglutide Helps Teens Lose Weight and Improve Heart Health

Diabetes drug semaglutide is surging in popularity. Is it safe?

Study Shows New Obesity Treatment Semaglutide Reduces Body Weight Regardless of Patient Characteristics

Study finds that obesity drug semaglutide supresses appetite, food cravings and energy intake

Diabetes Medication Semaglutide Reduces Excess Body Fat in People With Obesity

Semaglutide reduces excess body fat in people with obesity

Subcutaneous semaglutide vs. placebo as adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity

Semaglutide paired with intensive behavioral therapy showed triple weight loss vs placebo

A new study finds that 35% of people who took an obesity drug called Semaglutide lost more than 20% of their total body weight, after 68 weekly injections. About 75% lost more than 10% of their body weight. The average weight loss was 15.3 kg.